Analyze shared links from The Top Line

Another source it references often is Apple Podcast (1 links). The most cited link overall is a Other link, mentioned 100 times. Everything above comes straight from the public descriptions the creators wrote themselves. We don't add, remove, or assume anything.

Service

The table below shows each link, how many times The Top Line has used it, and which other podcasts have cited the same link.

Link	#	Other Shows
https://omnystudio.com/listener	100
https://www.fiercepharma.com/manufacturing/fda-allow-temporary-overseas-production-shore-supplies-chemo-drug	9	—
https://www.fiercepharma.com/manufacturing/failure-market-results-persisting-shortages-fda-oncology-director-says-report#:~:text=Ultimately%2C%20the%20FDA%20can	8	—
https://www.fiercepharma.com/pharma/full-approval-hand-eisai-and-biogen-kick-leqembis-alzheimers-launch-earnest	7	—
https://www.fiercejpmweek.com/	7
https://www.fiercepharma.com/manufacturing/emergent-makes-history-first-fda-nod-over-counter-naloxone	7
https://www.fiercepharma.com/pharma/national-cancer-center-network-reports-major-chemotherapy-shortages-calls-government	6	—
https://www.fiercepharma.com/pharma/ahead-next-months-fda-decision-emergent-aces-adcom-over-counter-narcan	6
https://www.fiercepharma.com/marketing/adapt-launches-regional-test-campaigns-to-encourage-opioid-users-loved-ones-to-keep	5
https://www.fiercepharma.com/pharma/eisai-biogens-leqembi-may-face-rollout-hurdles-now-experts-still-alzheimers-drug	5	—
https://www.fiercepharma.com/pharma/eyeing-1b-annual-sales-emergent-biosolutions-to-buy-narcan-maker-adapt-for-735m	5
https://www.fiercepharma.com/pharma/teva-and-sandoz-s-generics-have-launched-but-emergent-s-narcan-still-likely-to-thrive	5
https://www.fiercepharma.com/pharma/eisai-biogens-home-leqembi-clears-toxic-protein-alzheimers-disease-what-about-safety	4	—
https://www.fiercebiotech.com/research/voyager-therapeutics-adds-anti-amyloid-gene-therapy-alzheimers-pipeline	4	—
https://www.fiercebiotech.com/research/alzheimers-drug-improves-cognition-mice-tamping-down-inflammation	4	—
https://www.fiercebiotech.com/biotech/acumen-surges-early-alzheimers-data-suggest-next-gen-leqembi-rival-active	4	—
https://www.fiercebiotech.com/research/one-injection-cure-sickle-cell-disease-new-mrna-gene-therapy-researchers-are-giving-it	4	—
https://www.fiercepharma.com/manufacturing/fulfilling-promise-cell-gene-therapies-through-manufacturing-part-i	4	—
https://www.mckinsey.com/mhi/our-insights/closing-the-womens-health-gap-a-1-trillion-dollar-opportunity-to-improve-lives-and-economies	4
https://www.fiercebiotech.com/medtech/quest-launches-blood-test-alzheimers-disease-aimed-general-consumers	4	—
https://www.fiercebiotech.com/medtech/fda-links-four-deaths-recalled-abiomed-impella-pumps-after-tavr-collisions	4	—
https://www.fiercebiotechsummit.com/?utm_source=ppc&amp	4	—
https://www.fiercebiotech.com/biotech/its-time-fierce-biotechs-2023-fierce-15-nominations-are-now-open	4	—
https://www.fiercepharma.com/pharma/after-winning-full-fda-nod-leqembi-eisai-touts-promising-data-subcutaneous-version	3	—
https://www.fiercepharma.com/marketing/eisai-launches-digital-business-theoria-build-out-dementia-ecosystem-patients	3	—
https://www.fiercepharma.com/fiercepharmacom/fierce-50-reports	3
https://www.fiercepharma.com/pharma/top-20-pharma-companies-2022-revenue	3	—
https://www.fiercepharma.com/special-reports/2022-drug-approvals-after-aduhelm-fiasco-fda-endorsements-were-harder-come	3	—
https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-23	3	—
https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023	3	—
https://www.fiercebiotech.com/biotech/asco-after-keytruda-merck-builds-3-prong-cancer-strategy-stars-moderna-partnered-vaccine	2	—
https://www.fiercepharma.com/pharma/gileads-lenacapivir-approved-first-class-long-acting-hiv-injectable	2	—
https://www.fiercebiotech.com/biotech/asco-big-pharmas-double-down-past-wins-future-success-and-steer-clear-radioligands-and-cell	2	—
https://www.fiercepharma.com/pharma/after-fdas-ukoniq-pull-tg-therapeutics-wins-commercial-mulligan-briumvi-challenge-ocrevus	2	—
https://www.fiercepharma.com/special-reports/top-10-biopharma-ma-deals-2023	2	—
https://www.fiercepharma.com/pharma/braeburns-long-acting-brixadi-cleared-treat-opioid-use-disorder	2	—
https://www.fiercepharma.com/pharma/biogen-fdas-inappropriate-aduhelm-coordination-detailed-blistering-congressional-report	2	—
https://www.fiercepharma.com/pharma/roche-gets-lunsumio-across-fda-finish-line-offering-convenient-option-follicular-lymphoma	2	—
https://www.fiercepharma.com/pharma/2024-forecast-ma-saw-uptick-2023-expect-trend-continue	2	—
https://www.fiercebiotech.com/special-reports/fierce-medtechs-fierce-15-2023	2	—
https://www.fiercepharma.com/pharma/big-pharmas-top-10-highest-paid-ceos-2023	2	—
https://www.fiercepharma.com/pharma/fda-doc-outlines-apparent-agency-support-full-approval-biogen-eisais-leqembi	2	—
https://www.fiercepharma.com/pharma/analysts-prescription-big-pharma-take-ma-small-doses	2	—
https://www.fiercebiotech.com/medtech/asco-illumina-oncology-exec-need-democratize-genomic-profiling-cancer	2	—
https://www.fiercepharma.com/pharma/merck-challenges-hhs-medicare-drug-price-negotiations-lawsuit-alleging-constitutional	2	—
https://www.fiercebiotech.com/biotech/jjs-new-multiple-myeloma-combo-produces-deja-vu-96-carvykti-response	2	—
https://www.fiercepharma.com/pharma/moderna-makes-its-first-ever-acquisition-buying-japanese-dna-manufacturer-oriciro	2	—
https://www.fiercebiotech.com/special-reports/fierce-biotechs-rotten-tomatoes-2022	2	—
https://www.fiercebiotech.com/medtech/akili-launches-over-counter-version-attention-improving-video-game-adults-adhd	2	—
https://www.fiercepharma.com/pharma/first-redoseable-gene-therapy-approved-treat-rare-fragile-skin-disease-krystal-biotechs	2	—

About us Privacy Policy